WO2002072009A3 - Heterocyclic derivatives for the treatment of cancer and other proliferative diseases - Google Patents
Heterocyclic derivatives for the treatment of cancer and other proliferative diseases Download PDFInfo
- Publication number
- WO2002072009A3 WO2002072009A3 PCT/US2002/007001 US0207001W WO02072009A3 WO 2002072009 A3 WO2002072009 A3 WO 2002072009A3 US 0207001 W US0207001 W US 0207001W WO 02072009 A3 WO02072009 A3 WO 02072009A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- aryl
- heteroaryl
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02721289A EP1385465A4 (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
MXPA03008117A MXPA03008117A (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases. |
CA002440184A CA2440184A1 (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
IL15774002A IL157740A0 (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives and pharmaceutical compositions containing the same |
EA200300982A EA200300982A1 (en) | 2001-03-07 | 2002-03-07 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES |
BR0207846-5A BR0207846A (en) | 2001-03-07 | 2002-03-07 | Heterocyclic Derivatives for the Treatment of Cancer and Other Proliferative Diseases |
JP2002570969A JP2005506290A (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives for treating cancer and other proliferative diseases |
AU2002252227A AU2002252227A1 (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
NO20033883A NO20033883L (en) | 2001-03-07 | 2003-09-02 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27475101P | 2001-03-07 | 2001-03-07 | |
US60/274,751 | 2001-03-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002072009A2 WO2002072009A2 (en) | 2002-09-19 |
WO2002072009A3 true WO2002072009A3 (en) | 2003-10-16 |
Family
ID=23049469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/007001 WO2002072009A2 (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
Country Status (12)
Country | Link |
---|---|
US (1) | US7153875B2 (en) |
EP (1) | EP1385465A4 (en) |
JP (1) | JP2005506290A (en) |
AU (1) | AU2002252227A1 (en) |
BR (1) | BR0207846A (en) |
CA (1) | CA2440184A1 (en) |
EA (1) | EA200300982A1 (en) |
IL (1) | IL157740A0 (en) |
MX (1) | MXPA03008117A (en) |
NO (1) | NO20033883L (en) |
PL (1) | PL373912A1 (en) |
WO (1) | WO2002072009A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02002257A (en) | 1999-08-31 | 2002-09-30 | Maxia Pharmaceuticals Inc | Benzylidene thiazolidinediones and analogues and their use in the treatment of diabetes. |
CA2440184A1 (en) | 2001-03-07 | 2002-09-19 | Incyte San Diego, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
EP1377559A4 (en) | 2001-03-08 | 2005-09-28 | Incyte San Diego Inc | Rxr activating molecules |
US20030083357A1 (en) * | 2001-08-17 | 2003-05-01 | Magnus Pfahl | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
JP2005513026A (en) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | Hypercholesterolemia, dyslipidemia and other metabolic disorders; N-substituted heterocycles to treat cancer and other diseases |
US7053071B2 (en) | 2001-11-30 | 2006-05-30 | The Burnham Institute | Induction of apoptosis in cancer cells |
US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
CA2520172C (en) * | 2003-03-27 | 2012-10-02 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor |
FR2856401B1 (en) * | 2003-06-20 | 2010-02-12 | Galderma Res & Dev | NOVEL MODULATING COMPOUNDS OF PPARGAMMA RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS |
DE10351744A1 (en) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinones, their preparation and use as pharmaceuticals |
US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
EP2210869A1 (en) | 2005-04-08 | 2010-07-28 | Galderma Research & Development | New method for the preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
FR2884248B1 (en) * | 2005-04-08 | 2007-05-18 | Galderma Res & Dev | NOVEL PROCESS FOR THE PREPARATION OF 6- [3- (1-ADAMANTYL) -4-METHOXYPHENYL] -2-NAPHTHOIC ACID |
KR100814109B1 (en) | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same |
TW200815429A (en) * | 2006-04-11 | 2008-04-01 | Smithkline Beecham Corp | Thiazolidinedione derivatives as PI3 kinase inhibitors |
US20080255115A1 (en) * | 2007-04-11 | 2008-10-16 | Michael Gerard Darcy | Thiazolidinedione derivatives as pi3 kinase inhibitors |
PE20090288A1 (en) * | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS |
PE20090717A1 (en) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
AU2008326381B2 (en) * | 2007-11-21 | 2014-10-23 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating inflammation |
EP2674417A3 (en) | 2007-11-21 | 2014-04-09 | Decode Genetics EHF | Biaryl PDE4 inhibitors for treating inflammation |
CN102558088A (en) * | 2010-12-31 | 2012-07-11 | 中国科学院上海药物研究所 | Biphenyl methylene-2-sulpho-4-thiazolone compound as well as preparation method and application thereof |
WO2023121184A1 (en) * | 2021-12-21 | 2023-06-29 | (주)메디픽 | Substituted thiazolidinedione derivative compound, and pharmaceutical composition for preventing or treating cancer, comprising same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
DE2626348C3 (en) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantable dosing device |
JPS5538359A (en) | 1978-09-12 | 1980-03-17 | Hamari Yakuhin Kogyo Kk | Preparation of 2-(3-benzoylphenyl)-propionic acid |
US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
CA1325222C (en) | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Process for producing 4-biphenylylacetic acid |
EP0304493B1 (en) | 1987-03-11 | 1992-09-02 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene derivatives |
FI91869C (en) * | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Process for the preparation of benzoxazole derivatives as antidiabetic agents |
US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
US5223522A (en) | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
IE940525L (en) | 1988-05-25 | 1989-11-25 | Warner Lambert Co | Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents |
WO1993002060A1 (en) | 1991-07-22 | 1993-02-04 | Pfizer, Inc. | Process for the preparation of intermediates in the synthesis of chiral thiazolidine-2,4-dione derivatives |
EP0983991B1 (en) | 1992-04-22 | 2003-12-17 | Ligand Pharmaceuticals, Inc. | Compounds having selectivity for retinoid x receptors |
US5780676A (en) | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
ZA936492B (en) | 1992-09-10 | 1995-03-02 | Lilly Co Eli | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease. |
EP0671005A1 (en) | 1992-11-25 | 1995-09-13 | La Jolla Cancer Research Foundation | Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression |
US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
NZ279689A (en) | 1994-02-17 | 1997-08-22 | American Home Prod | Substituted biphenyl derivatives, preparation and pharmaceutical compositions thereof |
JPH09136877A (en) | 1995-06-16 | 1997-05-27 | Takeda Chem Ind Ltd | Heterocyclic compound, its production and use thereof |
EP0850067A4 (en) | 1995-07-17 | 1999-12-15 | Cird Galderma | Method for treating cancers using 6- 3- 1-adamantyl]-4-hydroxyphenyl] |
CN1196730A (en) | 1996-06-19 | 1998-10-21 | 雷迪博士研究基金会 | Novel polymorphic forms of troglitazone having enhanced anti-brabetic activity and process for their preparation |
CN1279902C (en) | 1996-07-08 | 2006-10-18 | 盖尔德马研究及发展公司 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents |
CA2300813A1 (en) | 1997-08-21 | 1999-03-04 | Hiroyuki Odaka | Anti-inflammatory agent |
WO1999024415A1 (en) | 1997-11-12 | 1999-05-20 | Institute Of Medicinal Molecular Design, Inc. | Retinoid receptor agonists |
US6262044B1 (en) * | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
KR20010099623A (en) | 1998-08-21 | 2001-11-09 | 비로파마 인코포레이티드 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
WO2000018748A1 (en) | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders |
AU3111700A (en) | 1998-12-04 | 2000-06-19 | Structural Bioinformatics Inc. | Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity |
WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
MXPA02002257A (en) * | 1999-08-31 | 2002-09-30 | Maxia Pharmaceuticals Inc | Benzylidene thiazolidinediones and analogues and their use in the treatment of diabetes. |
ATE345332T1 (en) | 1999-11-12 | 2006-12-15 | Fujimoto Brothers Co Ltd | 2-(N-CYANIMINO)THIAZOLIDINE-4-ONE DERIVATIVES |
FR2812876B1 (en) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS |
CA2440184A1 (en) | 2001-03-07 | 2002-09-19 | Incyte San Diego, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
EP1377559A4 (en) | 2001-03-08 | 2005-09-28 | Incyte San Diego Inc | Rxr activating molecules |
DE60204674T2 (en) | 2001-03-14 | 2006-05-18 | Eli Lilly And Co., Indianapolis | RETINOID X RECEPTOR MODULATORS |
EP1392326B1 (en) | 2001-04-04 | 2009-09-09 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
US20030083357A1 (en) * | 2001-08-17 | 2003-05-01 | Magnus Pfahl | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
JP2005513026A (en) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | Hypercholesterolemia, dyslipidemia and other metabolic disorders; N-substituted heterocycles to treat cancer and other diseases |
TW200304375A (en) * | 2001-12-06 | 2003-10-01 | Maxia Pharmaceuticals Inc | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer |
US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
CA2529154C (en) * | 2003-06-20 | 2013-05-07 | Galderma Research & Development, S.N.C. | Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions |
-
2002
- 2002-03-07 CA CA002440184A patent/CA2440184A1/en not_active Abandoned
- 2002-03-07 WO PCT/US2002/007001 patent/WO2002072009A2/en not_active Application Discontinuation
- 2002-03-07 MX MXPA03008117A patent/MXPA03008117A/en unknown
- 2002-03-07 EA EA200300982A patent/EA200300982A1/en unknown
- 2002-03-07 EP EP02721289A patent/EP1385465A4/en not_active Withdrawn
- 2002-03-07 US US10/094,142 patent/US7153875B2/en not_active Expired - Fee Related
- 2002-03-07 JP JP2002570969A patent/JP2005506290A/en active Pending
- 2002-03-07 IL IL15774002A patent/IL157740A0/en unknown
- 2002-03-07 BR BR0207846-5A patent/BR0207846A/en not_active Application Discontinuation
- 2002-03-07 PL PL02373912A patent/PL373912A1/en not_active Application Discontinuation
- 2002-03-07 AU AU2002252227A patent/AU2002252227A1/en not_active Abandoned
-
2003
- 2003-09-02 NO NO20033883A patent/NO20033883L/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
Also Published As
Publication number | Publication date |
---|---|
IL157740A0 (en) | 2004-03-28 |
NO20033883L (en) | 2003-11-05 |
PL373912A1 (en) | 2005-09-19 |
EP1385465A4 (en) | 2005-09-07 |
AU2002252227A1 (en) | 2002-09-24 |
JP2005506290A (en) | 2005-03-03 |
US7153875B2 (en) | 2006-12-26 |
US20020143182A1 (en) | 2002-10-03 |
EP1385465A2 (en) | 2004-02-04 |
BR0207846A (en) | 2005-09-13 |
CA2440184A1 (en) | 2002-09-19 |
WO2002072009A2 (en) | 2002-09-19 |
NO20033883D0 (en) | 2003-09-02 |
MXPA03008117A (en) | 2004-11-12 |
EA200300982A1 (en) | 2004-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002072009A3 (en) | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | |
BE2018C008I2 (en) | ||
WO2001019828A3 (en) | Kinase inhibitors as therapeutic agents | |
BG106340A (en) | Substituted oxoazaheterocyclyl compounds | |
AU8345491A (en) | Heterocyclic derivatives | |
TW200640900A (en) | 1-(2h)-isoquinolone derivative | |
PL1635835T3 (en) | 2-aminopyrimidine derivatives as raf kinase inhibitors | |
WO2005021497A3 (en) | Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones | |
MY138263A (en) | Therapeutic chroman compounds | |
WO2000068198A3 (en) | Heterosubstituted pyridine derivatives as pde 4 inhibitors | |
ZA200404752B (en) | 6-aminomorphinane derivatives method for the production and use thereof | |
CA2238875A1 (en) | Tri-aryl ethane derivatives as pde iv inhibitors | |
WO2000064874A3 (en) | Heterosubstituted pyridine derivatives as pde 4 inhibitors | |
AU4023093A (en) | Novel substituted tertiary amino compound or salt thereof | |
MY138826A (en) | 2,7-substituted indoles | |
AU2001274806A1 (en) | Sulfonamide derivatives | |
WO2002079753A3 (en) | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | |
UA66866C2 (en) | Synthesis of mopholine derivatives | |
SI1102765T1 (en) | PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C)QUINOLIZIN-3-ONES DERIVATIVES | |
GB0215392D0 (en) | Chemical compounds | |
MY129094A (en) | Condensed polycyclic compounds | |
AU2002214320A1 (en) | Imidazole derivatives, process for their preparation and their use | |
MXPA04005151A (en) | Therapeutic compounds. | |
WO2003076426A3 (en) | Pyridinyloxy derivatives as 5-ht receptor ligands | |
WO2002008227A3 (en) | Bicyclic hydantoin derivatives and combinatorial libraries thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 157740 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 373912 Country of ref document: PL Ref document number: 2002570969 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/008117 Country of ref document: MX Ref document number: 028062132 Country of ref document: CN Ref document number: 2440184 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 528641 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200300982 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002721289 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002721289 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0207846 Country of ref document: BR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002721289 Country of ref document: EP |